Afinity maturation and development of an anti-inflammatory monoclonal antibody

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/535931

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Antibodies are a relatively new class of drugs that directly target molecular mechanisms of disease. Antibody therapies, such as the breast cancer drug Herceptin, have significantly increased our arsenal of effective therapeutics. In collaboration with G2 Therapies, we will use cutting-edge genetic engineering technology to produce fully human antibodies for the treatment of inflammatory diseases, such as rheumatoid arthritis.

Funded Activity Details

Start Date: 01-01-2009

End Date: 01-01-2012

Funding Scheme: Career Development Fellowships

Funding Amount: $387,489.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Allergy

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Monoclonal antibodies | Protein engineering | Protein therapeutics

Related Links